Sensus Healthcare, Inc. Stock News

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Sensus (SRTS) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Sensus and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that a study published in Dermatologic Therapy demonstrates the safety and efficacy of the Company's superficial radiotherapy (SRT) techn...

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Sensus (SRTS) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Sensus and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Sensus (SRTS) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Sensus and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Investors can contact the law firm at no cost to learn more about recovering their losses

Investors can contact the law firm at no cost to learn more about recovering their losses

Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Javier Rampolla - Chief Financial Officer Joseph C. Sardano - Co-Founder, Chairman & CEO Michael J.

Sensus (SRTS) Q2 Revenue Falls 21%